Skip to content

Effectiveness of oestrogen pretreatment in patients with expected poor ovarian response (Poseidon groups 3 and 4) undergoing GnRH antagonist protocol: a randomized controlled trial

Effectiveness of oestrogen pretreatment in patients with expected poor ovarian response (Poseidon groups 3 and 4) undergoing GnRH antagonist protocol: a randomized controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064812
Enrollment
Unknown
Registered
2022-10-19
Start date
2022-11-15
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

intervention group:oestrogen pretreatment+GnRH antagonist protocol
control group:GnRH antagonist protocol

Sponsors

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Age (group 3: aged 35 years); 2. Decreased ovarian reserve (sinus follicle count (AFC) <5 and/or anti-Muller canal hormone (AMH) <1.2 ng/ml).

Exclusion criteria

Exclusion criteria: 1. Aged over 45 years; 2. Pre-implantation gene detection cycle (PGT); 3. Receiver of egg donation; 4. Body mass index (BMI) >= 30 kg/m^2; 5. History of ovarian surgery; 6. Endocrine disorders (diabetes mellitus, hyperprolactinemia, hypothyroidism, congenital adrenal hyperplasia, Cushing's syndrome, or polycystic ovary syndrome); 7. Untreated moderate to severe endometriosis, submucosal fibroids, multiple endometrial polyps, pelvic inflammation, uterine malformations, Asherman syndrome, and hydrosalpinx; 8. Patients with immune function and karyotype abnormalities; 9. Having a family history of thrombosis or high risk of thrombosis; 10. History of hypertension or hyperlipidemia.

Design outcomes

Primary

MeasureTime frame
number of oocytes retrieved;

Secondary

MeasureTime frame
number of retrieved metaphase II (MII) oocytes;average daily dose of exogenous gonadotropins;total exogenous gonadotropin dose;duration of ovarian stimulation;cycle cancellation rate;top quality embryos (TQE) rate;blastula formation rate;embryo implantation rate;clinical pregnant rate;miscarriage rate;hormone level and endometrial thickness at trigger;

Countries

China

Contacts

Public ContactSong Jingyan

The Affiliated Hospital of Shandong University of Traditional Chinese Medicine

hanlingjuzei91@126.com+86 18765800113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026